|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:approves
|
gptkb:2018
gptkb:Oncology
gptkb:non-Hodgkin_lymphoma
gptkb:rheumatoid_arthritis
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:bioequivalence
|
gptkb:Rituxan
|
|
gptkbp:class
|
gptkb:immunotherapy
|
|
gptkbp:clinical_trial
|
gptkb:Celltrion
multiple countries
Phase III
|
|
gptkbp:clinical_use
|
oncology
hematology
rheumatology
|
|
gptkbp:competitors
|
other biosimilars
|
|
gptkbp:cost_comparison
|
lower cost than Rituxan
|
|
gptkbp:developed_by
|
gptkb:Celltrion
|
|
gptkbp:dosage_form
|
solution for infusion
|
|
gptkbp:emaapproval_date
|
January 2019
|
|
gptkbp:financial_support
|
available for patients
|
|
gptkbp:formulation
|
sterile solution
|
|
gptkbp:healthcare
|
November 2018
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Truxima
|
|
gptkbp:indication
|
autoimmune diseases
|
|
gptkbp:ingredients
|
gptkb:rituximab
|
|
gptkbp:invention
|
patent expired
|
|
gptkbp:is_compared_to
|
gptkb:Rituxan
|
|
gptkbp:manufacturer
|
gptkb:Celltrion_Healthcare
|
|
gptkbp:marketed_as
|
gptkb:Europe
gptkb:Canada
gptkb:United_States
gptkb:Rituxan
|
|
gptkbp:mechanism_of_action
|
CD20 antigen targeting
|
|
gptkbp:name
|
Essential Medicines List
|
|
gptkbp:patient_population
|
gptkb:children
adults
|
|
gptkbp:pharmacokinetics
|
B-cell depletion
similar to Rituxan
|
|
gptkbp:provides_guidance_on
|
included in treatment guidelines
|
|
gptkbp:regulatory_compliance
|
approved
|
|
gptkbp:research
|
ongoing studies
|
|
gptkbp:route_of_administration
|
intravenous
|
|
gptkbp:safety_features
|
similar to Rituxan
|
|
gptkbp:sales
|
increasing
|
|
gptkbp:service_frequency
|
every 6 months
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
fever
chills
infections
infusion reactions
hypersensitivity reactions
tumor lysis syndrome
|
|
gptkbp:storage
|
2 to 8 degrees Celsius
|
|
gptkbp:trade
|
gptkb:Truxima
|
|
gptkbp:type
|
gptkb:monoclonal_antibody
|
|
gptkbp:bfsParent
|
gptkb:Celltrion
|
|
gptkbp:bfsLayer
|
6
|